Delamanid as a New Therapy in Tuberculosis

Abstract

Tuberculosis had become one of the top 10 fatal diseases in the world in 2015. The WHO's current recommendation is to provide an injection daily for ³ 8 months, with a total treatment duration of ³ 20 months. The lack of effective and dependable medications for the treatment of MDR TB threatensthe achievement of national and global TB treatment target programs. Tuberculosis is an infectious disease with a high rate of morbidity and mortality. Tuberculosis therapy has started to encounter resistance. Nevertheless, current resistance therapy administration has a high risk and low therapeutic success rate. Delamanid, as a newly considered medication, has shown promising efficacy and benefits in reducing the failure rate of tuberculosis therapy resistance.